Kaufman and colleagues vaccinated metastatic colorectal cancer patients with a CEA-ALVAC vaccine in combination with irinotecan, 5-FU and leucovorin and found that the CEA-specific T-cell response was unaffected by the chemotherapy (Kaufman et al, 2008). Here, CEACAM5 is linked to metastatic colorectal cancer.